Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis
MetadataShow full item record
CitationWang, Bo, Jessica M. Franklin, Wesley Eddings, Joan Landon, and Aaron S. Kesselheim. 2016. “Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis.” Edited by Dermot Cox. PLoS ONE 11 (3) (March 31): e0152195. doi:10.1371/journal.pone.0152195.
AbstractBackground: Following Food and Drug Administration (FDA) approval, many drugs are prescribed for non-FDA-approved (“off-label”) uses. If substantial evidence supports the efficacy and safety of off-label indications, manufacturers can pursue formal FDA approval through supplemental new drug applications (sNDAs). We evaluated the effect of FDA determinations on pediatric sNDAs for antipsychotic drugs on prescribing of these products in children.
Methods: Retrospective, segmented time-series analysis using new prescription claims during 2003-2012 for three atypical antipsychotics (olanzapine, quetiapine, ziprasidone). FDA approved the sNDAs for pediatric use of olanzapine and quetiapine in December 2009, but did not approve the sNDA for pediatric use of ziprasidone.
Results: During the months before FDA approval of its pediatric sNDA, new prescriptions of olanzapine decreased for both children and adults. After FDA approval, the increase in prescribing trends was similar for both age groups (P=0.47 for schizophrenia and bipolar disorder; P=0.37 for other indications). Comparable decreases in use of quetiapine were observed between pediatrics and adults following FDA approval of its pediatric sNDA (P=0.88; P=0.63). Prescribing of ziprasidone decreased similarly for pediatric and adult patients after FDA nonapproval of its pediatric sNDA (P=0.61; P=0.79).
Conclusions: The FDA’s sNDA determinations relating to use of antipsychotics in children did not result in changes in use that favored the approved sNDAs and disfavored the unapproved 3 sNDA. Improved communication may help translate the agency’s expert judgments to clinical practice.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:27364180
- HMS Scholarly Articles